

IN THE CLAIMS

Please amend the following of the claims which are pending in the present application:

1. (Currently amended) A pharmaceutical composition comprising processed ginseng extract obtained by the steps essentially comprising acid treating of ginseng extract and subsequent fermentation treating with lactic-acid bacteria or intestinal [[-]] bacteria, as an active ingredient in an amount effective to treat or prevent human or mammal suffering from brain strokes and brain diseases, together with a pharmaceutically acceptable carrier.
2. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases according to claim 1, wherein said ~~plant material~~ ginseng comprises the root, stem, petal, leaf, fruit and ~~their~~ tissue cultivates thereof.
3. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases according to claim 1, wherein said acid is acetic acid, citric acid, lactic acid or acid-containing food.
4. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases

according to claim 1, wherein said lactic acid bacteria ~~is belonged~~ belongs to Bifidobacterium genus or Lactobacillus genus bacteria.

5. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases according to claim 4, wherein said lactic acid bacteria comprises at least one or the mixture thereof selected from the group consisting of *Bifidobacterium infantis*, *Bifidobacterium bifidum*, *Lactobacillus lactis*, *Clostridium butyricum*, *Bifidobacterium* K-103, *Bifidobacterium* K-506, *Bifidobacterium* K-513, *Bifidobacterium* K-525, *Bifidobacterium* KK-1 and *Bifidobacterium* KK-2.

6. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases according to claim 1, wherein said intestinal bacteria ~~is belonged~~ belongs to Bacteriodes genus, Fusobacterium genus or Eubacterium genus bacteria.

7. (Currently amended) The pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases according to claim 6, wherein said intestinal ~~[[-]]~~ bacteria comprises at least one or the mixture thereof selected from the group consisting of *Bacteriodes* JY-6, *Bacteriodes stercoris*, *Fusobacterium* K-60 and *Eubacterium* L-8.

8. (Currently amended) A pharmaceutical composition[[s]] comprising saponin compounds selected from the group consisting of ginsenoside Rb₁, Rb₂, Rc, Rd, Re, Rf, Rgl, 20-ginsenoside Rg₃, and the mixture thereof, as an active ingredient in an amount effective to treat or prevent human or mammal brain stroke and brain diseases, together with a pharmaceutically acceptable carrier.
9. (Currently amended) The pharmaceutical composition according to ~~any of claims 1 to 8~~ claim 1, wherein said pharmaceutical composition is provided in an acceptable carrier as powder, granule, tablet, capsule, aqueous medicine or injection.
10. (Currently amended) A use of ginseng extract obtained by the steps essentially comprising acid treating of ginseng extract and subsequent fermentation treating with lactic-acid bacteria or intestinal ~~[[-]]~~ bacteria in the preparation of the medicament to prevent or treat brain stroke and brain diseases.
11. (Currently amended) A health care food comprising the extract as set forth in claim 1 and a sitologically acceptable additive to prevent ~~cancer or allergic~~ brain stroke and brain diseases.
12. (Currently amended) The health care food according to claim ~~[[12]]~~ 11, wherein said health care food is provided as beverage type.